How to improve DTC retention If youre a GLP-1 patient, a lot has to go right in months one to three
Consider this: while 60% of insurance appeals for GLP-1 drugs are successful, a staggering 88% of patients never challenge their denial
For example, a 2023 study in the UK found that 57% of adults attributed being overweight primarily to a lack of willpower (Beeken and Wardle, 2013)
Neurodegeneration and stroke after semaglutide and tirzepatide in patients with diabetes and obesity
However, given the associated risks of cardiovascular disease and various cancers, the benefits of these medications, such as better glycemic control, weight loss and improvement in cardiometabolic risk factors as well as other obesity complications, appear to outweigh the risks for most adults with obesity [143, 153]
This albumin-engineering strategy was also effective when applied with a therapeutic fusion partner, glucagon-like peptide 1 (GLP-1), resulting in a 2-fold increase in plasma half-life and prolonged efficacy in human FcRn transgenic mice